Inhibrx Biosciences, Inc. 4

Douglas G. Forsyth, through the Forsyth Family Trust, purchased 2,500 shares of Inhibrx Biosciences, Inc. common stock on 2026-09-08 at a weighted-average price of about $114.65 per share.

On 2026-09-08, Douglas G. Forsyth, a reporting insider of Inhibrx Biosciences, Inc., effected an open-market purchase of 2,500 shares of the company’s common stock at a weighted-average price of approximately $114.65 per share, for an estimated total cost of about $286,600. The transaction was executed in multiple trades within a price range of $114.36 to $114.689 per share. Following this acquisition, the Forsyth Family Trust Dated July 20, 2001, for which Forsyth serves as trustee and through which he indirectly beneficially owns the securities, held 227,064 shares of Inhibrx Biosciences common stock. The filing notes that the reporting person will provide full transaction-level pricing details upon request to the SEC, the issuer, or any security holder.

Filing Facts

CIK

2007919

Ticker

INBX

Form

4

Source Type

fda

Accession

0001240801-26-000004

Alert Tier

7